Your cart is currently empty!
Oxalinamo (Oxaliplatin) Injection
Generic brands for Oxaliplatin Injection Available in India Brand Name Oxalinamo Generic Name Oxaliplatin Strength 50mg, 100mg Manufacturer Shivnaam Tradelink Llp
Description
Description
This page contains brief details about the drug oxaliplatin, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Oxaliplatin is an anti-cancer drug that belongs to the platinum coordination complexes and alkylating agent approved for its medical use in treating advanced colorectal cancer on January 9, 2004.
Mechanism of Action of Oxaliplatin
Like other alkylating agents, oxaliplatin interferes with the development of DNA in a cancer cell. It stops cells from growing and multiplying and kills them. This helps to treat cancer which is caused by cells rapidly growing and dividing out of control.
Uses of Oxaliplatin
Oxaliplatin is indicated to treat adults with stage III colon cancer after surgery to remove the tumor. It is used with other anti-cancer medicines called 5-fluorouracil (5-FU) and leucovorin (LV) to treat adults with advanced colon or rectal cancer (colorectal cancer). It is also used as a combination therapy for Mantle cell lymphoma and Non-Hodgkin’s lymphoma ( a type of cancer that affects your lymphatic system, which is part of the body’s germ-fighting immune system). In combination with 5-fluorouracil and leucovorin, oxaliplatin is used as a second-line therapy to treat advanced or metastatic pancreatic cancer.
Oxaliplatin Dosage available
Oxaliplatin is given to you intravenously (IV) through your veins. The drug will be administered by a healthcare professional. Your physician will decide on the dose for administration based on the severity of the disease, weight, and height. Some medicines may be given to you before oxaliplatin to help prevent nausea and vomiting.
We can ship to :
News/Updates
References
1. HIGHLIGHTS OF PRESCRIBING INFORMATION. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021759s012lbl.pdf (Accessed on 19 December 2022)
2. Package leaflet: Information for the user. www.hpra.ie. https://www.hpra.ie/img/uploaded/swedocuments/2177427.PA0405_078_001.e3ff7724-1539-4e01-ae0b-83cef0ca53dc.000001Package%20leaflet.170117.pdf (Accessed December 19, 2022).
3. Tripathi KD. Essentials of Medical Pharmacology. Jaypee Brothers Medical Publishers; 2019:920-921. file:///C:/Users/BIS/Downloads/Essentials%20of%20Medical%20Pharmacology%20(%20PDFDrive%20).pdf (Accessed December 19, 2022).
4. Oxaliplatin – NCI. www.cancer.gov. Published October 5, 2006. Accessed December 19, 2022. https://www.cancer.gov/about-cancer/treatment/drugs/oxaliplatin
5. Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Current Oncology. 2011;18(1). doi:10.3747/co.v18i1.708 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031353/